U.S. Markets closed
  • S&P 500

    3,640.47
    -78.57 (-2.11%)
     
  • Dow 30

    29,225.61
    -458.13 (-1.54%)
     
  • Nasdaq

    10,737.51
    -314.13 (-2.84%)
     
  • Russell 2000

    1,674.93
    -40.31 (-2.35%)
     
  • Crude Oil

    81.73
    +0.50 (+0.62%)
     
  • Gold

    1,672.00
    +3.40 (+0.20%)
     
  • Silver

    18.87
    +0.16 (+0.84%)
     
  • EUR/USD

    0.9829
    +0.0090 (+0.9239%)
     
  • 10-Yr Bond

    3.7470
    +0.0420 (+1.13%)
     
  • Vix

    31.84
    +1.66 (+5.50%)
     
  • GBP/USD

    1.1176
    +0.0291 (+2.6700%)
     
  • USD/JPY

    144.3680
    +0.2460 (+0.1707%)
     
  • BTC-USD

    19,449.74
    -105.71 (-0.54%)
     
  • CMC Crypto 200

    444.40
    -1.58 (-0.35%)
     
  • FTSE 100

    6,881.59
    -123.80 (-1.77%)
     
  • Nikkei 225

    26,422.05
    +248.07 (+0.95%)
     

Massive Bio Continues to Grow in Europe

·2 min read

Three senior executives join Massive Bio, which is expanding its operations in Europe with Series B investments

NEW YORK, September 23, 2022--(BUSINESS WIRE)--Massive Bio, which uses its proprietary artificial intelligence-based platform to match cancer patients to clinical trials regardless of where they live or their financial circumstances, is expanding its operations in Europe. With support from Series B investments received in the first half of this year, Massive Bio announced the hiring of three new team members who will help expand the company's global operations, intensify its marketing activities, develop new data sets and products, and expand its M&A efforts. The new recruits are Toygun Onaran, who will serve as Head of Strategy; Mert Sarı, who will be Regional Manager; and Sinan Fındık, who comes on board as Clinical Research and Data Manager.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005244/en/

Massive Bio's expanding presence in Europe will allow the company to continue its mission of ensuring that all cancer patients receive treatment under fair and favorable conditions, said Çağlar Demirbağ, Director of International Partnerships, which manages the company’s operations outside of the United States, adding that "there are about 4 million patients diagnosed with cancer annually in Europe. With the steps we have taken in the last two years, we have been ensuring that thousands of cancer patients in Spain, Italy, France, Germany, Romania, Poland, and Greece are matched to appropriate clinical trials. This is also enabling that these patients receive the best treatment free of charge."

"The current changes we are making today will help us better reach and support more cancer patients in the future," added Erkan Terzi, Massive Bio's Vice President of Global Marketing. Terzi said, "At Massive Bio, we work on three continents in 32 different functional areas in our marketing efforts. Our recent updates, newsletters, infographics, new video production, digital-asset improvements, content writing, and advertising management continue to help us create a more comprehensive and effective patient-use case. The technologies we use and the integrated studies we create with different units enable us to work more effectively in the business focus."

About Massive Bio

Founded in New York City in 2015, Massive Bio aims to provide access to clinical trials for cancer patients worldwide, regardless of where they live or their financial circumstances.

You can reach Massive Bio via 100KSINGULARITY@massivebio.com, Twitter, LinkedIn, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220923005244/en/

Contacts

Media
Merve Sahin
msahin@massivebio.com